B-Cell Non-Hodgkin’s Lymphoma: Epidemiology Forecast to 2033
Summary
Non-Hodgkin’s lymphoma (NHL) represents a group of cancers that develop in the lymphatic system. Individuals with NHL experience uncontrolled malignant white blood cells, rendering the immune system incapable of effectively fighting off infections. Among all malignant lymphomas, the 90% are composed of NHL, making it among the most prevalent hematological adult cancers (Ekströ Smedby et al., 2008).
NHL is segmented by its histology into B-cell, T-cell, and natural killer lymphocyte lymphoma, with B-cell lymphoma constituting 80─85% of the three subtypes. B-cell lymphoma is distinguished into further subtypes, each of which exhibits its own unique pathology and behavior. Among them, diffuse large B-cell lymphoma (DLBCL) is the most prevalent at 33-51% of cases, followed by follicular lymphoma (FL) at 18-51% of cases. Other common B-cell NHLs include marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL), which compose 10-20% and 4-5% of cases, respectively. Each subtype is characterized by specific segmentations, including the distinction of DLBCL into germinal (GCB) and non-germinal center B-cell (non-GCB), as well as the subclassification of FL by histological features into grades 1,2, and 3 (Shustik et al., 2011; Singh et al., 2020).
Scope
- This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for B-cell NHL in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiology forecast for the diagnosed incident and five-year prevalent cases of B-cell NHL. The diagnosed incident and five-year diagnosed prevalent cases of B-cell NHL are segmented by age (18 years and older), sex, and subtype (DLBCL, FL, MZL, and MCL). Furthermore, diagnosed incident and five-year diagnosed prevalent cases of each subtype are segmented by relevant subtype-specific clinical features, including the distinction between GCB and non-GCB DLBCL, FL grade, bulky and non-bulky disease among stage II FL and MCL cases, and Ann Arbor staging (stages I─IV) for all four subtypes. Finally, five-year diagnosed prevalent cases of all subtypes are segmented into cases that have relapsed and those that are in remission or active.
The B-Cell Non-Hodgkin's Lymphoma Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global B-cell NHL markets.
- Quantify patient populations in the global B-cell NHL markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for B-cell NHL therapeutics in each of the markets covered.
- Understand magnitude of the B-cell NHL population by age, sex, histology, and subtype-specific stage at diagnosis.
- About GlobalData
- 1 B-Cell Non-Hodgkin’s Lymphoma: Executive Summary
- 1.1 Catalyst
- 1.2 Related reports
- 1.3 Upcoming reports
- 2 Epidemiology
- 2.1 Disease background
- 2.2 Risk factors and comorbidities
- 2.3 Global and historical trends
- 2.4 7MM forecast methodology
- 2.4.1 Sources
- 2.4.2 Forecast assumptions and methods
- 2.4.3 Forecast assumptions and methods: diagnosed incident cases of B-cell NHL - 7MM
- 2.4.4 Forecast assumptions and methods: diagnosed incident cases of diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma
- 2.4.5 Forecast assumptions and methods: diagnosed incident cases of B-cell NHL by stage
- 2.4.6 Forecast assumptions and methods: five-year diagnosed prevalent cases of B-cell NHL
- 2.4.7 Forecast assumptions and methods: five-year diagnosed prevalent cases of diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma
- 2.4.8 Forecast assumptions and methods: five-year diagnosed prevalent cases of B-cell NHL by stage
- 2.4.9 Forecast assumptions and methods: five-year diagnosed prevalent cases of diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma that progress from local and regional to advanced stages
- 2.5 Epidemiological forecast for B-cell NHL (2023-33)
- 2.5.1 Diagnosed incident cases of B-cell NHL
- 2.5.2 Age-specific diagnosed incident cases of B-cell NHL
- 2.5.3 Sex-specific diagnosed incident cases of B-cell NHL
- 2.5.4 Diagnosed incident cases of B-cell NHL by subtype
- 2.5.5 Diagnosed incident cases of diffuse large B-cell lymphoma by Ann Arbor staging
- 2.5.6 Diagnosed incident cases of follicular lymphoma by Ann Arbor staging
- 2.5.7 Diagnosed incident cases of marginal zone lymphoma by Ann Arbor staging
- 2.5.8 Diagnosed incident cases of mantle cell lymphoma by Ann Arbor staging
- 2.5.9 Five-year diagnosed prevalent cases of B-cell NHL
- 2.5.10 Age-specific five-year diagnosed prevalent cases of B-cell NHL
- 2.5.11 Sex-specific five-year diagnosed prevalent cases of B-cell NHL
- 2.5.12 Five-year diagnosed prevalent cases of B-cell NHL by subtype
- 2.5.13 Five-year diagnosed prevalent cases of diffuse large B-cell lymphoma by Ann Arbor staging
- 2.5.14 Five-year diagnosed prevalent cases of follicular lymphoma by Ann Arbor staging
- 2.5.15 Five-year diagnosed prevalent cases of marginal zone lymphoma by Ann Arbor staging
- 2.5.16 Five-year diagnosed prevalent cases of mantle cell lymphoma by Ann Arbor staging
- 2.6 Discussion
- 2.6.1 Epidemiological forecast insight
- 2.6.2 Limitations of the analysis
- 2.6.3 Strengths of the analysis
- 3 Appendix
- 3.1 Bibliography
- 3.2 Primary market research - prescriber survey
- 3.3 About the Authors
- 3.3.1 Epidemiologist
- 3.3.2 Reviewers
- 3.3.3 Vice President of Disease Analysis and Intelligence
- 3.3.4 Global Head and EVP of Healthcare Operations and Strategy
- List of Tables
- Table 1: Summary of newly added data types
- Table 2: Summary of updated data types
- Table 3: B-cell NHL Lugano cancer stages
- Table 4: B-cell NHL Ann Arbor cancer stages
- Table 5: Risk factors and comorbidities for B-cell NHL
- Table 6: High-prescribing physicians surveyed, by country
- List of Tables
- Table 1: Summary of newly added data types
- Table 2: Summary of updated data types
- Table 3: B-cell NHL Lugano cancer stages
- Table 4: B-cell NHL Ann Arbor cancer stages
- Table 5: Risk factors and comorbidities for B-cell NHL
- Table 6: High-prescribing physicians surveyed, by country" "
- List of Tables
- Table 1: AD: Key metrics in the 7MM
- Table 2: Risk factors and comorbidities for AD
- Table 3: Treatment guidelines for AD
- Table 4: AD approvals across 7MM
- Table 5: Top 10 deals by value, 2019-25
- Table 6: AD market - global drivers and barriers, 2023-33
- Table 7: Key events impacting sales for AD in the US, 2023-33
- Table 8: AD market - drivers and barriers in the US, 2023-33
- Table 9: Key events impacting sales for AD in the 5EU, 2023-33
- Table 10: AD market - drivers and barriers in the 5EU, 2023-33
- Table 11: Key events impacting sales for AD in Japan, 2023-33
- Table 12: AD market - drivers and barriers in Japan, 2023-33
- Table 13: High-prescribing physicians (non-KOLs) surveyed, by country" "
- List of Tables
- BT Global Services Ltd, Key Facts
- BT Global Services Ltd, Key Employees
- BT Global Services Ltd, Major Products and Services
- BT Global Services Ltd, History
- BT Global Services Ltd, Key Competitors
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook